Trial Profile

To study SCY-247

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SCY-247 (Primary)
Indications Aspergillosis; Candidiasis
Focus Therapeutic Use
Sponsors SCYNEXIS

Most Recent Events

11 May 2026 Status changed from planning to recruiting.
11 May 2026 According to SCYNEXIS media release, company announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the third quarter of 2026
21 Jan 2026 According to SCYNEXIS media release, company expect to initiate the trial in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com